HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

Ferraz-Amaro, Iván; Hernández-Hernández, María; Armas-González, Estefanía; Sánchez-Pérez, Hiurma; Machado, José David; Dı́az-González, Federico

doi:10.1007/s10067-020-04961-4

Cited by 11 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HDL CEC impairment has been reported in various rheumatologic autoimmune diseases, such as RA and systemic lupus erythematosus (SLE) [190][191][192][193][194]. In SLE, HDL CEC was inversely related to subclinical carotid atherosclerosis [195].…”

Section: Rheumatologic Diseasesmentioning

confidence: 99%

“…Data point to changes in HDL composition, with a reduction in antioxidant proteins, such as paroxonase [190] and the increase in proinflammatory molecules, such as SAA [196] or oxidized fatty acids [197]. Few studies have reported reduced CEC in patients with psoriatic arthritis [194,198] and anchylosing spondylitis [199] compared to controls.…”

Section: Rheumatologic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Adorni

Ronda

Bernini

et al. 2021

Cells

View full text Add to dashboard Cite

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

show abstract

Section: Rheumatologic Diseasesmentioning

confidence: 99%

Section: Rheumatologic Diseasesmentioning

confidence: 99%

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Adorni

Ronda

Bernini

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…In CKD, HDL accumulates SAA, pulmonary surfactant protein B (PSPB), lipoprotein associated phospholipase A2, apoC-III and symmetric dimethylarginine (SDMA) [ 112 , 134 , 135 ]. In CKD patients undergoing hemodialysis, HDL-associated SAA and PSPB are associated with cardiovascular events and all-cause mortality independently of HDL-C plasma concentrations [ 112 , 136 ]. In particular, SAA accumulation blunts HDL’s- protective properties towards endothelial cells, such as the promotion of NO production and the inhibition of ROS formation and expression of pro-inflammatory adhesion molecules [ 114 ].…”

Section: Hdl and Endothelial Cell Dysfunctionmentioning

confidence: 99%

The Endothelium Is Both a Target and a Barrier of HDL’s Protective Functions

Robert

Osto

Eckardstein

2021

Cells

View full text Add to dashboard Cite

The vascular endothelium serves as a barrier between the intravascular and extravascular compartments. High-density lipoproteins (HDL) have two kinds of interactions with this barrier. First, bloodborne HDL must pass the endothelium to access extravascular tissues, for example the arterial wall or the brain, to mediate cholesterol efflux from macrophages and other cells or exert other functions. To complete reverse cholesterol transport, HDL must even pass the endothelium a second time to re-enter circulation via the lymphatics. Transendothelial HDL transport is a regulated process involving scavenger receptor SR-BI, endothelial lipase, and ATP binding cassette transporters A1 and G1. Second, HDL helps to maintain the integrity of the endothelial barrier by (i) promoting junction closure as well as (ii) repair by stimulating the proliferation and migration of endothelial cells and their progenitor cells, and by preventing (iii) loss of glycocalix, (iv) apoptosis, as well as (v) transmigration of inflammatory cells. Additional vasoprotective functions of HDL include (vi) the induction of nitric oxide (NO) production and (vii) the inhibition of reactive oxygen species (ROS) production. These vasoprotective functions are exerted by the interactions of HDL particles with SR-BI as well as specific agonists carried by HDL, notably sphingosine-1-phophate (S1P), with their specific cellular counterparts, e.g., S1P receptors. Various diseases modify the protein and lipid composition and thereby the endothelial functionality of HDL. Thorough understanding of the structure–function relationships underlying the multiple interactions of HDL with endothelial cells is expected to elucidate new targets and strategies for the treatment or prevention of various diseases.

show abstract

“…Psoriatic arthritis (PsA) is associated with an increased risk of CV disease [4,5] and CV events [6]. Besides, PsA often exhibits an increased risk of metabolically linked comorbidities such as obesity, insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, and others [7]. For example, metabolic syndrome [8] and diabetes [9] are more common among patients with PsA than the general population and are also associated with disease severity.…”

Section: Introductionmentioning

confidence: 99%

The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background and objectives: Psoriatic arthritis (PsA) is associated with several comorbidities, including among others an increased risk of cardiovascular (CV) disease, atherosclerosis, metabolic syndrome, hypertension dyslipidemia, and diabetes. The purpose of the present study was to determine how the number of CV risk factors correlates with disease related data such as disease activity. Materials and Methods: Cross-sectional study that encompassed 305 patients who fulfilled the CASPAR criteria for PsA were assessed for lipid profile, disease activity measurements, and the presence of six traditional CV risk factors (diabetes mellitus, dyslipidemia, hypertension, obesity, chronic kidney disease, and smoking status). A multivariable regression analysis, adjusted for age, sex, and disease duration, was performed to evaluate if the number of classic CV risk factors was independently related with specific features of the disease, including disease activity. Results: Disease duration was found to be higher, after adjustment for age and sex, in patients with 1 or 2, and 3 or higher CV factors, compared to those patients without CV risk factors. Similarly, DAPSA (Disease Activity in PSoriatic Arthritis score) was found to be independently upregulated in patients with a higher number of CV risk factors. In this sense, as DAPSA score increases the odds ratio (OR) of having 1 or 2 (OR 1.12 (95% confidence interval (CI) 1.03–1.21), p = 0.010), and 3 or higher (OR 1.15 (95% CI 1.04–1.26), p = 0.004) CV factors was significantly higher compared to no CV risk factors category. This was independently found after adjustment for age, sex, and disease duration. Conclusions: PsA patients with a higher number of CV risk factors exhibit an upregulated disease activity compared to those without them. This is independent of disease duration and other demographics factors.

show abstract

HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

Cited by 11 publications

References 39 publications

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

The Endothelium Is Both a Target and a Barrier of HDL’s Protective Functions

The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis

Contact Info

Product

Resources

About